1,3-dicarboxy-7-oxabicyclo[2.2.1]hept-5-ene

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1,3-dicarboxy-7-oxabicyclo[2.2.1]hept-5-ene
• 英文别名: 7-Oxabicyclo[2.2.1]hept-5-ene-1,3-dicarboxylic acid；7-oxabicyclo[2.2.1]hept-5-ene-1,3-dicarboxylic acid
• 化学式: C₈H₈O₅
• 分子量: 184.149
• InChiKey: KGTDKBSHFCXAHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  糠酸（呋喃甲酸） 、 丙烯酸 在 对苯二酚 作用下， 160.0 ℃ 、101.33 kPa 条件下， 反应 10.0h， 生成 1,3-dicarboxy-7-oxabicyclo[2.2.1]hept-5-ene 、 1,2-diacetylmethyl ester-7-oxabicyclo[2.2.1]hept-5-ene
  参考文献：
  名称：

  一种7-氧杂二环[2.2.1]庚-5-烯单体及其制备 方法和应用

  摘要：

  本发明公开了一种7‑氧杂二环[2.2.1]庚‑5‑烯单体及制备方法和应用。该7‑氧杂二环[2.2.1]庚‑5‑烯单体采用生物基糠酸类化合物为原料，与丙烯酸、丙烯酸酯在阻聚剂和Lewis酸催化剂存在下发生Diels‑Alder反应，经过减压蒸馏去除未反应原料得到7‑氧杂二环[2.2.1]庚‑5‑烯单体。本发明制备方法简单、高效、副产物少，原料糠酸类化合物由玉米芯发酵法制备的糠醛氧化得到，原料来源广泛，成本低廉，且可持续发展。本发明制备的单体结构中含有羧酸或羧酸酯双官能团，可广泛应用于生物基聚酯、环氧树脂、聚酰胺、聚氨酯等领域。

  公开号：

  CN105566341B

文献信息

• N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
  申请人：Novartis AG

  公开号：US10450273B2

  公开（公告）日：2019-10-22

  The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.

  本发明涉及式 (I) 的杂环化合物 其中所有变量如说明书中所定义；能够调节 CFTR 的活性。本发明进一步提供了制造本发明化合物的方法及其治疗用途。本发明进一步提供了其制备方法、医疗用途，特别是用于治疗和管理包括囊性纤维化和相关疾病在内的疾病或紊乱。
• N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE
  申请人：Novartis AG

  公开号：EP3504194B1

  公开（公告）日：2021-08-18
• N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease
  申请人：Novartis AG

  公开号：US20180072673A1

  公开（公告）日：2018-03-15

  The invention relates to heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.